金融工程专题报告 公司治理专题系列报告二：基于多因子框架的中证 500 指数增强模型 证券分析师 王雪莹 022-23839121 wangxy4430@bhzq.com 核心观点： 研究背景与理论介绍 在 A 股市场的指数体系中，中证 500 是量化投资领域指数增强策略的 重要标的，该指数完整覆盖 31 个申万一级行业，包含电子、医药生物、 电力设备等多个战略性新兴产业，成分股多为处于成长期的优质企业， 兼具流动性与成长性双重优势，其成分股权重结构呈现出极致分散、风 险高度均衡的特征。截至 2026 年 3 月 18 日，以中证 500 指数为跟踪 标的的基金全市场合计达 249 只，总管理规模 1982.02 亿元，其中指 数增强型基金数量达 169 只，规模合计 565.19 亿元。 从投资逻辑来看，公司治理水平是决定企业长期健康发展的核心内生动 力，更是影响股票长期收益的关键因素。良好的公司治理能够有效规范 企业经营行为、优化资源配置效率、保护股东权益，进而提升企业的核 心竞争力与盈利能力，而财务指标作为企业经营成果与治理水平的量化 载体，能够直观、准确地反映企业的治理效率与经营质量，是筛选优质 标的 ...

智通财经APP获悉，昭衍新药(06127)早盘涨超14%，截至发稿，涨14.54%，报22.3港元，成交额7651.06 万港元。 消息面上，昭衍新药发布年度业绩，2025年，公司实现营业收入16.58亿元，同比下降17.87%；归属于 上市公司股东的净利润2.98亿元，同比增长302.08%。另外，公司整体在手订单金额约为26亿元，新签 订单金额约为26亿元，同比均有所增长。 公告显示，净利润的增长主要源于生物资产公允价值变动带来的收益。期内，生物资产公允价值变动带 来净收益4.76亿元。据悉，昭衍新药的生物资产主要是用于非临床项目评价的非人灵长类实验模型，也 就是所谓的"实验猴"。 ...

Group 1 - The report highlights that Chaoyun Group has maintained high dividends for six consecutive years, with revenue and profit both showing year-on-year growth, indicating a sustainable growth outlook for its product matrix [4][5] - In 2025, Chaoyun Group achieved a revenue of 1.988 billion RMB, a year-on-year increase of 9.24%, and a net profit of 224 million RMB, up 9.98% year-on-year, with a comprehensive gross margin of 52.61% [4][5] - The company’s home care products performed well, with revenue from this segment reaching 1.715 billion RMB, a year-on-year increase of 5.0%, while the pet business saw a significant growth of 74.3% [5][6] Group 2 - Jianmin Group's revenue for 2025 was 3.370 billion RMB, a decrease of 3.85% year-on-year, but the fourth quarter showed a strong recovery with an 82.69% increase in net profit [10][11] - The pharmaceutical industrial segment of Jianmin Group reported a revenue of 2.025 billion RMB, a year-on-year increase of 15.91%, driven by strong sales of prescription and OTC products [11][12] - The company is focusing on brand development and innovation, with key products showing significant sales growth, indicating a strong recovery in its core business [11][12] Group 3 - The report on Yimeng Biotech indicates that the B7H3 ADC drug has shown excellent efficacy in treating metastatic castration-resistant prostate cancer (mCRPC), with promising clinical trial results [13][14] - The drug has received fast track designation from the FDA, highlighting its potential in the market [14][15] - The clinical study included 146 patients, showing a median radiographic progression-free survival of 11.3 months, indicating strong therapeutic potential [15][16] Group 4 - Pop Mart reported a revenue of 37.12 billion RMB in 2025, a year-on-year increase of 184.7%, with adjusted net profit rising by 284.5% [18][19] - The company has seen a significant increase in online sales, which accounted for 44.3% of total revenue, reflecting a shift in consumer purchasing behavior [21][22] - The number of IPs generating over 2 billion RMB in revenue has increased, with the "Star People" IP showing a remarkable growth of 1602% [25][26] Group 5 - CIMC Vehicles reported a revenue of 20.18 billion RMB in 2025, a decrease of 3.9% year-on-year, but with a strong performance in the Chinese market, where semi-trailer sales increased by 15% [28][29] - The company anticipates a recovery in the North American market in 2026, with significant order rebounds indicating a potential turnaround [29][30] - The report emphasizes the company's strategic positioning in the global market, particularly in the southern regions, which are expected to drive future growth [28][29] Group 6 - Power Development reported a revenue of 5.293 billion RMB in 2025, a decrease of 6.4% year-on-year, but maintained a high profit margin despite market challenges [32][33] - The company achieved a high dividend payout ratio of 123%, reflecting its commitment to returning value to shareholders [33][34] - The report outlines ongoing projects that are expected to enhance production capacity significantly in the coming years, indicating strong growth potential [34][35] Group 7 - Bluestar Technology is recognized as a leader in adsorption separation materials, with significant growth driven by innovation and market demand in various sectors [37][38] - The company is positioned to benefit from the growing market for small nucleic acid drugs, with projections indicating substantial growth in this area [38][39] - The report forecasts revenues of 2.733 billion RMB for 2025, with a strong growth trajectory expected in subsequent years [39]

摘要 廖市无双："系统性慢牛"如何演绎下去？20260329 市场重心下移，上证指数波动区间由 4,000-4,200 点下移至 3,700- 3,800 点，80%筹码已处于套牢状态。 确定性支撑位在 3,755 点（0.382 回撤位），3,700-3,800 点为核心 防御带，4,040 点以上为中期显著压力区。 预计 4 月中下旬市场有望依托 W 底或复杂底部企稳，开启周线级反弹， 但受流动性及外部冲击影响，B 浪反弹概率高于创新高。 行业表现分化，仅公用事业与电力设备维持连阳，TMT 及非银板块跌幅 居前，反映市场风险偏好显著下降。 二季度配置建议"新旧能源+周期消费"，关注算电协同、电力设备、 红利资产（银行/交运）及医药农业。 操作策略主张择时优先于选股，建议在 3,700-3,800 点区间逢低吸纳， 临近 4,000 点高抛，通过区间操作降低成本。 Q&A 如何评估上周的市场判断与本周市场实际走势之间的一致性与差异？ 上周预判市场因中东地缘冲突及 A 股创业板权重股的抱团吸金现象（主要集中 在新能源和光模块领域）而需要调整，并预计调整将触及 2025 年 9 至 10 月 的成交密集区。同时 ...

Core Viewpoint - The A-share market is experiencing a positive trend in Q1 2026 earnings forecasts, with a significant majority of companies reporting expected profit increases, indicating overall market optimism [1]. Group 1: Earnings Forecasts - As of March 29, 2026, 18 companies have disclosed their Q1 earnings forecasts, with 88.89% expecting profit increases, including 10 companies forecasting substantial growth, 5 slight increases, and 1 company turning a loss into profit [1]. - The sectors showing the highest growth are machinery, pharmaceuticals, and basic chemicals, driven by both volume and price increases [1]. Group 2: Notable Companies - Oukeyi is expected to report a net profit of 180 million to 220 million yuan, representing a year-on-year increase of 2248.9% to 2770.9%, primarily due to the rise in hard alloy tool prices and a low base effect from the previous year [1]. - Fuxiang Pharmaceutical forecasts a net profit of 52 million to 75 million yuan, with a year-on-year growth of 2222.67% to 3250.01%, benefiting from the booming demand in the new energy sector [2]. - Kuncai Technology is projected to achieve a net profit of 60 million to 80 million yuan, marking a year-on-year increase of 151.56% to 235.41%, driven by the recovery in titanium dioxide prices [2]. Group 3: Growth Drivers - Wanbangde is expected to report a net profit of 165 million yuan, reflecting a year-on-year increase of 985.4%, attributed to its strategic shift from generic to innovative drugs and increased R&D investment [3]. - Gude Electric Materials anticipates a revenue growth of 41.41% to 53.89%, with a net profit forecast of 48 million to 51 million yuan, driven by successful expansion into copper-aluminum composite materials [3]. Group 4: Other Notable Performances - Aolaide expects a net profit of 70 million to 85 million yuan, with a year-on-year growth of 175.2% to 234.17%, due to its competitive advantage in evaporator equipment [4]. - Tianshan Aluminum is projected to achieve a net profit of 2.2 billion yuan, a year-on-year increase of 107.92%, benefiting from the capacity release of its green low-carbon aluminum project [4].

3月18日提示《公司的智能电关节等产品已用于四足机器狗、双足人形机器人及轮式机器人》，富临 精工自19日连续7个交易日上涨，累计涨幅28%； 3月23日提示《公司三大主业共振，一季报预增超22倍》，富祥药业自24日连涨4日，累计涨幅 35%； 3月23日提示《公司发布第五代高压实磷酸铁锂正极材料压实密度达2.704g/cm3》，龙蟠科技自24 日连续4个交易日放量拉升，累计涨幅20.6%； 前言 面对每晚海量的公告无从下手？《公告臻选》助你高效决策！专业筛选每晚最重要的关键公告，提供通 俗易懂的深度解读，揭示复杂术语背后的投资机会。助你10分钟掌握市场全貌，决胜开盘之前。 【臻选回顾】 3月25日提示《公司为英伟达批量供应光模块耦合、晶圆测试设备》，罗博特科26日、27日分别上 涨4.7%、5.2%。 ③风电+光伏+储能+智能电网+数据中心+算力！公司自主研制的新一代固态变压器（SST）样机下 线。 点击解锁付费内容，捕捉每天公告中的"黄金机会"！ 3月24日提示《公司800G LPO光模块已小批量出货 1.6T配合客户JDM开发》，铭普光磁25日、26 日连续涨停； 【今日速览】 ①锂电池+钠离子电池+固态 ...

Group 1 - The report highlights that the overseas situation remains a key factor affecting the new stock market, with a low risk appetite suggesting a focus on relatively low-positioned directions [1][12] - The new stock market has shown weak performance over several weeks, with an average decline of approximately 2.6% since 2025, and only about 25.5% of new stocks achieving positive returns [1][28] - The report suggests that potential investment opportunities may arise from high-low rotation in relatively low-positioned stocks, especially if the overseas situation stabilizes [2][12] Group 2 - Specific investment directions include focusing on industries with long-term themes such as AI computing power, commercial aerospace, and energy exports, which have significant growth potential [3][12] - The report also mentions the importance of monitoring sectors like innovative pharmaceuticals and new consumption, which may see periodic interest and can be strategically rotated based on expected catalysts [3][12] Group 3 - Upcoming new stocks include companies like Yuelong Technology, Longyuan Co., and Taijin New Energy, which are expected to be listed soon [4][35] - The average issuance price-earnings ratio for new stocks is reported to be around 21.8X, indicating a stable pricing environment despite the low risk appetite in the market [7][35] - The report emphasizes the need for caution in the short term due to the overall market risk appetite being relatively low, which may affect the performance of newly listed stocks [7][35]

金融工程 证 券 研 究 报 告 【金工周报】（20260323-20260327） 形态学翻多，后市或先扬后抑 本周回顾 本周市场普遍下跌，上证指数单周下跌 1.09%，创业板指单周下跌 1.68%。 A 股模型： 短期：成交量模型中性。特征龙虎榜机构模型中性。特征成交量模型看空。智 能算法沪深 300 模型看空，智能算法中证 500 模型看空。 中期：涨跌停模型中性。上下行收益差模型绝大部分宽基指数中性。月历效应 模型中性。 长期：长期动量模型中性。 综合：A 股综合兵器 V3 模型看空。A 股综合国证 2000 模型看空。 港股模型： 中期：成交额倒波幅模型看空。上下行收益差模型中性，上下行收益差相似模 型中性。 本周行业指数涨少跌多，涨幅前五的行业为：基础化工、有色金属、综合、电 力及公用事业、医药，跌幅前五的行业为：非银行金融、计算机、农林牧渔、 电子、综合金融。从资金流向角度来说，除有色金属、基础化工、建材外所有 行业主力资金净流出，其中电子、计算机、电力设备及新能源、通信、机械主 力资金净流出居前。 本周股票型基金总仓位为 97.06%，相较于上周增加了 31 个 bps，混合型基金 总仓位 8 ...

Market Overview - The Hang Seng Index decreased by 1.3% this week, while the Hang Seng Composite Index fell by 1.2%. Small-cap stocks outperformed large-cap and mid-cap stocks, with the Hang Seng Small Cap Index rising by 1.0% [1] - The pharmaceutical sector showed resilience, increasing by 3.8%, while the defense and military industry saw a significant decline of 8.3% [1] Valuation Levels - The valuation of the Hang Seng Index decreased by 1.8% to 10.8x, with the Hang Seng Composite Index also at 10.8x, down by 1.0% [2] - The Hang Seng Biotechnology Index saw a notable increase in valuation by 4.9% to 24.5x, while the Hang Seng High Dividend Index dropped by 3.1% to 7.5x [2] - Among 29 industries, 12 experienced an increase in valuation, with Agriculture and Forestry rising by 12.7% and Consumer Services by 7.5% [2] Earnings Expectations - The EPS for the Hang Seng Index increased by 0.4%, while the Hang Seng Composite Index saw a slight decrease of 0.2% [3] - The ROE Defensive Strategy saw a significant upward revision of 13.9%, while the ROE Offensive Strategy was revised down by 2.8% [3] - A total of 10 industries had upward revisions in EPS, with Comprehensive Finance seeing the largest increase of 36.0%, while 18 industries had downward revisions, with Electronics down by 9.2% [3]

Investment Rating - The report maintains a "Buy" rating for WuXi AppTec (02268.HK) with a target price of HKD 68.47, reflecting a strong long-term growth outlook despite short-term challenges [3][5]. Core Insights - WuXi AppTec is positioned as a global leader in ADC CRDMO, with a solid order backlog and capacity expansion plans. The company is expected to experience robust long-term growth, with adjusted net profit forecasts for 2025-2027 at RMB 14.8 billion, RMB 20.3 billion, and RMB 27.1 billion respectively [3][10]. - The company achieved a revenue of RMB 59.4 billion in 2025, representing a year-on-year growth of 46.7%, with overseas revenue contributing 85% of total sales, indicating a significant increase in international market penetration [10]. - The report highlights the company's strong order intake, with new orders totaling USD 1.33 billion in 2025, a 41% increase year-on-year, and a backlog of USD 1.49 billion, up 50.3% year-on-year, ensuring a solid revenue foundation [10]. Financial Performance Summary - Revenue projections for 2023 to 2027 are as follows: RMB 2,124 million (2023), RMB 4,052 million (2024), RMB 5,944 million (2025), RMB 8,129 million (2026), and RMB 10,844 million (2027), with respective year-on-year growth rates of 114.4%, 90.8%, 46.7%, 36.8%, and 33.4% [4]. - The company's gross profit is expected to reach RMB 21.4 billion in 2025, with a gross margin of 36.0%, reflecting operational efficiency improvements and increased capacity utilization [4][10]. - The net profit attributable to the parent company is projected to be RMB 1.48 billion in 2025, with a net profit margin of 24.9% [4][10].